Estrogen synthesis inhibitors for breast cancer: An introductory overview

Endocrine-Related Cancer

Volumn 3, Issue 1, 1996, Pages 1-8

  Santen, R J ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIESTROGEN; AROMATASE INHIBITOR; ENZYME INHIBITOR; ESTRADIOL; ESTROGEN RECEPTOR; ESTROGEN SYNTHESIS INHIBITOR; UNCLASSIFIED DRUG;

BREAST CANCER; FEMALE; HUMAN; REVIEW;

EID: 0029923911     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/erc.0.0030001     Document Type: Review

References (54)

1. Alonso-Munoz MC, Ojeda-Gonzalez MB, Beltran-Fabreyat M, Dorca-Ribugent J, Lopez-Lopez L, Borras-Balada J, Cardenal-Alemany F, Gomez-Batiste X, Fabregat-Mayol J & Viladiu-Quemada P 1988 Randomized trial of tamoxifen versus aminoglutethimide and versus combined tamoxifen and aminoglutethimide in advanced postmenopausal breast cancer. Oncology 45 350-353.
2. Andersson S 1995 Molecular biology of types II and III human 17β-HSD. Proceedings of the International Symposium of DHEA Transformation into Androgens and Estrogens in Target Tissues: Intracrinology, p 11.
3. Brinton LA, Daling JR, Liff JM, Schoenberg JB, Malone KE, Stanford JL, Coates RJ, Gammon MD, Hanson L & Hoover RN 1995 Oral contraceptives and breast cancer risk among younger women. Journal of the National Cancer Institute 87 827-835.
4. Bulun SE, Sharda G, Rink J, Sharma S & Simpson ER 1996 Distribution of aromatase P450 transcripts and adipose fibroblasts in the human breast. Journal of Clinical Endocrinology and Metabolism (In Press).
5. Cartensen JF, Tesdorpf JG, Kaufman M, Markus MM, Husen B, Leenders F, Jakob F, de Launoit Y & Adamski J 1996 Characterization of 17β-hydroxysteroid dehydrogenase IV. Journal of Endocrinology (In Press).
6. Colditz GA, Hankinson SE, Hunter DJ, Willet WC, Manson JE, Stampfer MJ, Hennekens C, Rosner B & Speizer FE 1995 The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. New England Journal of Medicine 332 1589-1593.
7. D'Andrea AD, Yoshimura A, Youssoufian H, Zon LI, Roo JW & Lodish HF 1991 The cytoplasmic region of the erythropoietin receptor contains nonoverlapping positive and negative growth-regulatory domains. Molecular and Cellular Biology 11 1980-1987.
8. DeSombre ER, Thrope SM, Rose C, Blough RR, Anderson KW, Rasmussen BB & King WJ 1986 Prognostic usefulness of estrogen receptor immunocytochemical assays for human breast cancer. Cancer Research 46 4256s-4264s.
9. Durgam VR & Tekmal RR 1994 The nature and expression of int-5, a novel MMTV integration locus gene in carcinogen-induced mammary tumors: Cancer Letters 87 179-186.
10. Encarnacion CA, Mangold G, Coronado E, Yee D, Fuqua S & Osborne CK 1993 Development of enhanced hormonal response after estrogen withdrawal in MCF-7 tumors. Proceedings of the American Association for Cancer Research 34 246 Abstract No. 1464.
11. Fisher B, Osborne CK, Margolese R & Bloomer W 1993 XXXII: Neoplasms of the breast. In Cancer Medicine, edn 3, vol 2, pp 1706-1774. Philadelphia: Lea & Febiger.
12. Furth J 1982 Hormones as etiological agents in neoplasia. In Comprehensive Treatise, Etiology: Chemical and Physical Carcinogenesis, edn 2, pp 89-134. Ed FF Becker. New York: Plenum Press.
13. Gale KE, Andersen JW, Tormey DC, Mansour EG, Davis TE, Horton J, Wolter JM, Smith TJ & Cummings FJ 1994 Hormonal treatment for metastatic breast cancer. An Eastern Cooperative Oncology Group Phase II trial comparing aminoglutethimide to tamoxifen. Cancer 73 354-361.
14. Gottardis MM, Jiang S-Y, Jeng M-H & Jordan VC 1989 Inhibition of tamoxifen-stimulated growth of an MCF-7 tumor variant in athymic mice by novel steroidal antiestrogens. Cancer Research 49 4090-4093.
15. Gunson DE, Steele RE & Chau RY 1995 Prevention of spontaneous tumours in female rats by fadrozole hydrochloride, an aromatase inhibitor. British Journal of Cancer 7272-75.
16. Henderson BE, Bernstein L & Ross RK 1993 III-3: Hormones and the etiology of cancer. In Cancer Medicine, edn 3, vol 1, pp 223-232. Philadelphia: Lea & Febiger.
17. IARC Group 1979 IARC Mono graphs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans, Sex Hormones (II), vol 21. Lyon: International Agency for Research into Cancer.
18. Kirschenbaum A, Ren M & Levine AC 1993 Enhanced androgen sensitivity in serum-free medium of a subline of the LNCaP human prostate cell line. Steroids 58 439-444.
19. Labrie F & Veilleux R 1986 A wide range of sensitivities to androgens develops in cloned Shionogi mouse mammary tumor cells. The Prostate 8 293-300.
20. Labrie F, Veilleux R & Fournier A 1988 Low androgen levels induce the development of androgen-hypersensitive cell clones in Shionogi mouse mammary carcinoma cells in culture. Journal of the National Cancer Institute 80 1138-1147.
21. Li FP, Schneider JA & Kantor AF 1993 IV: Cancer epidemiology. In Cancer Medicine, edn 3, vol 1, pp 332-339. Philadelphia: Lea & Febiger.
22. Lippman ME 1988 Epidemiology of breast cancer. In Diagnosis and Management of Breast Cancer, pp 1-9. Eds ME Lippman, AS Lichter & DN Danforth. Philadelphia: WB Saunders Co.
23. Lipton A, Harvey HA, Santen RJ, Boucher A, White D, Bernath A, Dixon R, Richards G & Shafik A 1982 A randomized trial of aminoglutethimide versus tamoxifen in metastatic breast cancer. Cancer 50 2265-2268.
24. Love RR, Mazess RB, Barden HS, Epstein S, Newcomb PA, Jordan VC, Carbone PP & DeMets DL 1992 Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. New England Journal of Medicine 326 852-856.
25. Lu Q, Nakamura J, Savinov A & Brodie A 1995 Evidence of aromatase expression and proliferation in human breast cancers. Proceedings of the 77th Annual Meeting of the Endocrine Society, Abstract P2-655, p 454.
26. McCarty KS, Szabo E, Flowers JL, Cox EB, Leight GS, Miller L, Knorath J, Soper JT, Budwit DA, Creasman WT, Seigler HF & McCarty KS Sr 1986 Use of a monoclonal anti-estrogen receptor antibody in the immunohistochemical evaluation of human tumors. Cancer Research (Suppl) 46 4244s-4248s.
27. Maruca J, Kulin HE & Santner SJ 1983 Pertubation of negative feedback sensitivity in agonadal patients undergoing estrogen replacement therapy. Journal of Clinical Endocrinology and Metabolism 56 53-59.
28. Masamura S, Santner SJ, Heitjan DF & Santen RJ 1995 Estradiol deprivation causes estradiol hypersensitivity in human breast cancer cells. Journal of Clinical Endocrinology and Metabolism 80 2918-2925.
29. Medina D 1973 Preneoplastic lesions in mouse mammary tumorigenesis. Methods in Cancer Research 7 3-53.
30. Medina D 1988 The preneoplastic state in mouse mammary tumorigenesis. Carcinogenesis 9 1113-1119.
31. Morris VL, Rao TR, Kozak DA, Gray DA, Lee Chan ECM, Cornell TJ, Taylor CB, Jones RF & McGrath CM 1991 Characterization of Int-5, a locus associated with early events in mammary carcinogenesis. Oncogene Research 6 53-63.
32. Multiple Authors 1986 Symposium on estrogen receptor determination with monoclonal antibodies. Cancer Research 46 4233s-4312s.
33. Nissen ED & Kent DR 1975 Liver tumors and oral contraceptives 1975. Obstetrics and Gynaecology 46 460.
34. Oerter Klein K, Demers LM, Santner SJ, Baron J, Cutler GB Jr & Santen RJ 1995 Use of ultrasensitive recombinant cell bioassay to measure estrogen levels in women with breast cancer receiving the aromatase inhibitor, letrozole. Journal of Clinical Endocrinology and Metabolism 80 2658-2660.
35. Osborne CK, Wiebe VJ, McGuire WL, Ciocca DR & DeGregorio MW 1992 Tamoxifen and the isomers of 4-hydroxytamoxifen in tamoxifen-resistant tumors from breast cancer patients. Journal of Clinical Oncology 10 304-310.
36. Oshima H & Simons SS Jr 1992a Modulation of glucocorticoid induction of tyrosine aminotransferase gene expression by variations in cell density. Endocrinology 130 2106-2112.
37. Oshima H & Simons SS Jr 1992b Modulation of transcription factor activity by a distant steroid modulatory element. Molecular Endocrinology 6 416-428.
38. Peltoketo H, Isomaa V, Poutanen M & Vihko V 1996 Expression and regulation of 17β-hydroxysteroid dehydrogenase type I. Journal of Endocrinology (In Press).
39. Penning TM 1996 17β-Hydroxysteroid dehydrogenase: inhibitors and inhibitor design. Endocrine-Related Cancer 3 41-56.
40. Reed MJ, Purohit A, Woo LWL & Potter BVL 1996 The development of steroid sulphatase inhibitors. Endocrine-Related Cancer 3 9-23.
41. Safe SH 1995 Environmental and dietary estrogens and human health: is there a problem? Environmental Health Perspectives 103 346-351.
42. Santen RJ 1993 Clinical use of aromatase inhibitors in breast carcinoma. In Cancer Medicine, edn 3, pp 865-877. Eds JF Holland, E Frei, RC Bast, DW Kufe, DL Morton & RR Weichselbaum. Philadelphia: Lea & Febiger.
43. Santen RJ, Samojlik E & Wells SA 1980 Resistance of the ovary to blockade of aromatization with aminoglutethimide. Journal of Clinical Endocrinology and Metabolism 51 473-477.
44. Santen RJ, Manni A, Harvey H & Redmond C 1990 Endocrine treatment of breast cancer in women. Endocrine Reviews 11 221-265.
45. Santen RJ, Martel J, Hoagland M, Naftolin F, Roa L, Harada N, Hafer L, Zaino R & Santner SJ 1994 Stromal spindle cell distribution of aromatase in human breast tumors. Journal of Clinical Endocrinology and Metabolism 79 627-632.
46. Santner SJ, Leszczynski D, Wright C, Manni A, Feil PD & Santen RJ 1986 Estrone sulfate: a potential source of estradiol in human breast cancer tissues. Breast Cancer Research and Treatment 7 35-44.
47. Santner SJ, Kaseta J, Bernstein L, Pauley RJ, Smith HS & Santen RJ 1995 Regulation of aromatase in stromal cells from human breast cancer and peripheral breast tissue: effects of dexamethasone, phorbol esters and cAMP. Proceedings of the 77th Annual Meeting of the Endocrine Society. Abstract P2-654, p 454.
48. Siiteri PK 1978 Steroid hormones and endometrial cancer. Cancer Research 38 4360.
49. Simons SS, Oshima H & Szapary D 1992 Higher levels of control: modulation of steroid feedback mechanism in man. Molecular Endocrinology 6 995-1002.
50. Simpson ER, Mahendroo MS, Means GD, Kilgore MW, Hinshelwood MM, Graham-Lorence S, Amarneh B, Ito Y, Fisher CR, Michael MD, Mendelson CR & Bulin SE 1994 Aromatase cytochrome P450, the enzyme responsible for estrogen biosynthesis. Endocrine Reviews 15 342-355.
51. Smith TI, Harris AL, Morgan M, Ford HT, Gazet J-C, Harmer CL, White H, Parsons CA, Villardo A, Walsh G & McKinna JA 1981 Tamoxifen versus aminoglutethimide in advanced breast carcinoma: a randomized crossover trial. British Medical Journal 283 1432-1434.
52. Tekmal RR & Durgam VR 1995 The overexpression of int-5/Aromatase, a novel MMTV integration locus gene, is responsible for D2 mammary tumor cell proliferation. Cancer Letters 88 147-155.
53. Wakeling AE, Dukes M & Bowler J 1991 A potent specific pure antiestrogen with clinical potential. Cancer Research 51 3867-3873.
54. Zumoff B 1981 Abnormal plasma hormone levels in women with breast cancer. In Hormones and Breast Cancer, pp 143-168. Eds MC Pike, PK Siitert & CV Welsch. Cold Spring Harbor: Cold Spring Harbor Laboratory Press.